BDBM50194721 CHEMBL3908310::US9714234, 4

SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O

InChI Key InChIKey=LEOYMYOSQPPAAS-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 50194721   

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 2.30nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 2.80nMAssay Description:Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 4.40nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 4.60nMAssay Description:Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 4.60nMAssay Description:Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 19nMAssay Description:Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 630nMAssay Description:Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 990nMAssay Description:Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 990nMAssay Description:Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 1.20E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 2.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
US Patent